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Abstract 
Although cirrhosis is a key risk factor for the development of hepatocellular carcinoma (HCC), mounting evidence 
indicates that in a subset of patients presenting with non-alcoholic steatohepatitis (NASH), HCC manifests in the 
absence of cirrhosis. Given the sheer size of the non-alcoholic fatty liver disease (NAFLD) epidemic, and the 
dismal prognosis associated with late-stage primary liver cancer, there is an urgent need for HCC surveillance 
in the NASH patient. In the present study, adult male mice randomized to control diet or a fast food diet (FFD) 
were followed for up to 14 mo and serum level of a panel of HCC-relevant biomarkers was compared with liver 
biopsies at 3 and 14 mo. Both NAFLD Activity Score (NAS) and hepatic hydroxyproline content were elevated 
at 3 and 14 mo on FFD. Picrosirius red staining of liver sections revealed a filigree pattern of fibrillar collagen 
deposition with no cirrhosis at 14 mo on FFD. Nevertheless, 46% of animals bore one or more tumors on their 
livers confirmed as HCC in hematoxylin-eosin-stained liver sections. Receiver operating characteristic (ROC) 
curves analysis for serum levels of the HCC biomarkers osteopontin (OPN), alpha-fetoprotein (AFP) and 
Dickkopf-1 (DKK1) returned concordance-statistic/area under ROC curve of > 0.89. These data suggest that 
serum levels of OPN (threshold, 218 ng/mL; sensitivity, 82%; specificity, 86%), AFP (136 ng/mL; 91%; 97%) and 
DKK1 (2.4 ng/mL; 82%; 81%) are diagnostic for HCC in a clinically relevant model of NASH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. NASH and HCC: The spectrum of NAFLD is shown with classical progression (blue block arrows) from simple 
steatosis to NASH to NASH with fibrosis, cirrhosis and HCC. Nevertheless, it is becoming evident that NASH can lead 
to HCC (red arrow) in the absence of cirrhosis, and in certain cases, prior to the development of even advanced fibrosis. 
Introduction 
Given the diabetes, obesity and metabolic syndrome epidemics, non-alcoholic fatty liver disease (NAFLD) has 
reached epidemic proportions.1,2 Left untreated, NAFLD, which starts as simple steatosis, can progress (Figure 
1) to non-alcoholic steatohepatitis (NASH), NASH with increasing levels of fibrosis, cirrhosis and hepatocellular 
carcinoma, (HCC).1-3 A number of studies has reported that cirrhosis, secondary to alcoholism or hepatitis C 
virus (HCV), is a major risk factor for HCC and liver-related death.4-6 In fact, the American Association of Liver 
Disease (AASLD) recommends screening of cirrhotics every 6 mo for HCC.7,8 Nevertheless, mounting evidence9-
12 suggests that NASH can also progress to HCC in the absence of cirrhosis (Figure 1).  Most alarming, data 
from a number9-13 of clinical studies indicates that ~50% of NASH patients presents with HCC without cirrhosis. 
 
 
 
 
 
Liver biopsy-microscopic evaluation remains the gold standard for diagnosis of HCC9.  Given that seeding of the 
tumor in the needle tract occurs only in 1–3% of biopsies14 and taking into account the logistics, risks and patient 
compliance issues associated with liver biopsies, ultrasonography with or without serum alpha-fetoprotein (AFP), 
an HCC biomarker, is being used to diagnose HCC.7-8 However, a major challenge associated with HCC 
surveillance in patients with NASH is that obesity compromises the completeness of an ultrasound examination 
of the liver.13 This necessitates computed tomography or magnetic resonance imaging scans which are 
expensive, both in terms of costs and patient compliance. Results from liver imaging can also be confounded by 
the presence of benign incidentelomas such as hamartomas, resulting in incorrect diagnosis. Use of a single 
HCC biomarker such as AFP is also fraught with risk of misdiagnosis - in many instances HCCs do not produce 
AFP; on the other hand, this biomarker can be elevated in the absence of HCC.  Patients with NASH-HCC often 
present with larger tumors and have a worse prognosis than those with HCC secondary to other etiologies13. 
Additionally, it is fully recognized7,8,15 that therapeutic strategy and prognosis in HCC is linked to disease stage, 
with Barcelona Clinic Liver Cancer (BCLC) stage 0-A patients having better outcomes. Taken together, these 
findings suggest that HCC surveillance is urgently needed in the ~ 16 million NASH patients and the ~ 5 million 
NASH with fibrosis patients within the United States alone16. Furthermore, from the patient’s and loved ones 
perspective, correct diagnosis of HCC is as important as early diagnosis. 
 
 In the present study, we employed a clinically relevant, mammalian model17,18 of diet-induced liver disease to 
develop a framework for diagnosis of HCC in NASH without cirrhosis. Mice on standard lab chow or a fast food 
diet (FFD; a.k.a. Western diet) were followed for up to 14 mo.  With each animal acting as its own control, serum 
level of a panel of HCC-related biomarkers was evaluated and compared with the absence or presence of HCC. 
Receiver operating characteristic (ROC) curves for serum levels of HCC biomarkers were generated and for 
biomarkers with concordance-statistic or area under ROC curve (AUROC) > 0.8, thresholds identified. A Boolean 
logic gate-linked diagnostic framework for HCC in his model of NASH is presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
 
The animal protocol was reviewed and approved by the local institutional animal care and use committee. Mice 
had access to food and water ad libitum throughout the course of the in-life protocol. 
 
Fast Food Diet (FFD) Model of Liver Disease: Adult male C57BL/6 mice (20-22 g) were randomized to 
standard lab chow (control) or FFD (rodent diet with 40 kcal% fat (mostly Primex), 20 kcal% fructose and 2% 
cholesterol; D09100301, Research Diets, NJ) for up to 14 mo. Animals were sacrificed at 3 or 14 mo into their 
diets.  Each individually tracked animal acted as its own serum and liver control. 
 
NASH and HCC: At sacrifice, livers were examined (gross) for the absence or presence of tumors by two 
independent observers. Several biopsies were obtained from each liver and fixed in formalin (10%); whenever 
tumors were present, both tumors and remote liver were biopsied. Hematoxylin-eosin (H&E)-stained liver 
sections were studied under a microscope by blinded trained observers for evaluation of both, NAFLD Activity 
Score (NAS; worsening 0-8 scale; 0-3 steatosis; 0-3 inflammation; 0-2 hepatocyte ballooning)19 and HCC.20,21 
NAS was averaged from three independent observers whereas HCC diagnosis required confirmation from both 
gross liver and microscopic observation by 2 trained and independent observers. 
 
Liver Fibrosis: At sacrifice, total liver hydroxyproline, a surrogate for collagen, was quantified from liver biopsies 
using a colorimetric assay as described previously22. Picrosirius red staining of liver sections followed by 
semiquantitation (Bioquant) of extracellular fibrillar collagen22 was performed by a blinded observer.  
 
 
Serum-based Biomarkers: Commercially available enzyme-linked immunosorbent assay (ELISA) kits for 
murine serum samples were used for determination of biomarker levels. In many instances, following a pilot 
study, serum samples had to be diluted (saline) and the ELISAs rerun so that sample levels remained within the 
standard curve. Table 1 lists the biomarkers evaluated and information on the ELISA kit. Aspartate 
transaminase (AST) and alanine transaminase (ALT) were measured (Northwell Health, NY) in serum samples 
from the 3 mo cohort. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Data Analysis: Data are presented as mean ± standard error or mean. Student’s T-test or one-way analysis of 
variance followed by Tukey’s post-hoc test was used to compare data between groups. A p < 0 .05 was deemed 
significant. ROC curves were generated in Excel using Pivot Tables and AUROC, sensitivity (Sn), specificity (Sp) 
and cutoffs/thresholds calculated.29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomarkers ELISA Kit
alpha fetoprotein (AFP) MAFP00; R&D
lens culinaris agglutinin A-reactive fraction of AFP (AFP-L3) MBS724605; MYBioSource
des γ carboxyprothrombin (DCP aka PIVKA-II) MBS2516006; MYBioSource
glypican -3 MBS705612; MYBioSource
osteopontin MOST00; R&D
golgi protein-73 (GP73) MBS024709; MYBioSource
Dickkopf-related protein 1 (DKK1) DY1765; R&D
Table 1. Biomarker Query Set: Based on 
literature23-28, levels of 7 biomarkers 
circulating in blood were evaluated. 
Results 
 
Gross Observations 
 
Of the 24 animals randomized to FFD for 14 mo, 11 animals, i.e. 46%, exhibited one or more tumors (Figure 2) 
on their livers with subsequent confirmation of HCC under microscope.   
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 stratifies the animals entered into the study 
on the basis of diet type, duration on diet and 
presence or absence of HCC. By 3 mo on FFD while 
livers had a distinct fatty phenotype there were no 
visible tumors. By 14 mo on FFD, approximately half 
the animals had visible liver tumors. 
 
 
 
 
Table 2. Liver Phenotype: Of the 76 animals entered into the 
study, 11 of 24 animals from the 14 mo FFD cohort exhibited 
HCC positive liver tumors.
Figure 2. Hepatic Tumors with FFD: (A, B) Many animals on an FFD for 14 mo exhibited one or more 
tumors on the liver. (C) Representative livers from 14 mo - control (#1) and FFD (#s 14, 13 and 18) cohorts 
are shown. Large tumors are visible on the livers of #s 13 and 18. 
n Diet Duration on Diet HCC
8 control 3 mo no
32 FFD 3 mo no
12 control 14 mo no
13 FFD 14 mo no
11 FFD 14 mo yes
At both 3 mo and 14 mo on FFD, animals presented with increased liver mass and liver:body mass ratio with 
these values being highest in livers presenting with tumors (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of ROC curves for liver mass and liver to body mass ratio yielded AUROCs of 0.83 and 0.82, 
respectively (Figure 4). Clinically, these endpoints are of little or no diagnostic value and thresholds were not 
computed. 
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Figure 3. Liver Phenotype: Animals randomized to FFD exhibited increased hepatic mass and liver to body mass 
ratio. This was evident by 3 mo (A, B) and at 14 mo (C, D).  14 mo-FFD animals with liver tumors (HCC FFD) had 
the highest values for these variables. #, p< 0.01 vs. control; * p<0.01 vs. FFD 
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Figure 4. Liver Phenotype and HCC: AUROCs of liver mass (A) and liver to body mass ratio (B) to diagnose HCC 
were 0.83 and 0.82, respectively. 
Liver Histopathology and Liver Function Tests. 
 
Microscopic observation (Figure 5) of H&E stained liver sections from the FFD cohort showed hallmark 
characteristics of NASH. In fact, compared to the control diet cohort, NAS (Figure 5) was elevated at both 3 mo 
and 14 mo in the FFD cohort. Within the 14 mo FFD cohort, livers that presented with tumors on gross 
observation exhibited mixed pattern trabecular and acinar HCC (Figure 5). Comparing the 14 mo diet cohorts, 
the HCC livers had the highest NAS (Figure 5). Determination of liver function tests at the 3 mo time period 
demonstrated elevated AST (142±6 vs.69±17; p<0.01) and ALT (110±15 vs. 47±9;  p<0.05) in the FFD vs. control 
diet cohort. 
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Figure 5. FFD Model of Liver Disease: (A) H&E-stained sections (4X) from representative 14 mo control diet or 14-
mo FFD livers. Livers from the FFD cohort exhibited characteristic features of NASH. Some of the FFD livers showed 
HCC characterized by a demarcated zone (arrows) across which were multiple proliferating nucleii. (B) Representative 
livers (20X) from animals on FFD for 14 mo showing multiple proliferating nuclei (arrows), characteristic of HCC. These 
HCC livers also exhibited steatosis and inflammation. (C) Increased NAS was evident in livers of animals on FFD for 3 
mo.  (D) At 14 mo, livers presenting with HCC had the highest NAS. #, p< 0.01 vs. control; * p<0.01 vs. FFD
Next, we determined this model of NASH is accompanied by increasing levels of liver fibrosis. Animals 
randomized to FFD for 3 mo exhibited a 50% higher liver hydroxyproline content, a marker of fibrosis, compared 
with animals randomized to the control diet (Figure 6). At 14 mo, animals on FFD, but free of HCC, had >4-fold 
higher liver hydroxyproline content than animals on a control diet (Figure 6). Liver hydroxyproline content was 
highest in the 14 mo HCC FFD cohort, 10-fold greater than the 14 mo control diet cohort. The AUROC for liver 
hydroxyproline to diagnose HCC was 0.9 (Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. NASH with Fibrosis and HCC. Livers from animals on a control diet or FFD were examined for 
fibrosis using the marker hydroxyproline. A) 3 mo on FFD was associated with a 50% increase in liver 
hydroxyproline. B) By 14 mo, the HCC-free FFD cohort exhibited > 4-0 fold higher liver hydroxyproline 
content compared to the control group. At this timepoint, the HCC FFD cohort had the highest level of liver 
hydroxyproline. #, p< 0.01 vs. control; * p<0.01 vs. FFD. C) The AUROC of liver hydroxyproline as a 
diagnostic for HCC was 0.9. 
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Cirrhosis develops from fibrosis30 although the two are pathologically distinct. At the fibrosis stage, the amount 
of collagen increases and the ratio of fibroconnective tissue versus liver cellular tissue increases; liver lobular 
structures are intact. Cirrhosis consists of two pathological features fibroconnective tissue hypertrophy and 
pseudolobule formation30. With cirrhosis, the liver's fundamental structure is deformed, and the framework of the 
liver begins collapse. To determine whether the HCC FFD cohort had progressed beyond fibrosis to cirrhosis, 
Picrosirius red-stained sections of livers were examined. While livers from the control diet cohort exhibited little, 
or no Picrosirius red staining, livers from the FFD cohort classified as HCC exhibited a filigree pattern of 
Picrosirius red staining (Figure 7), with a collagen proportionate area consistent with fibrosis but not cirrhosis31. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. HCC in NASH 
with Fibrosis: A and B) 
Picrosirius red stained 
representative liver 
sections (4X (A) and 10X 
(B)) showing fibrosis 
(but not cirrhosis) in 
HCC positive livers. C) 
Collagen proportionate 
area in HCC FFD livers 
<< 25% typically 
observed in cirrhosis. 
Serum HCC Biomarkers 
Next, serum levels of biomarkers listed in Table 1 were measured in mice on control diets or FFD for 3 mo or 14 
mo. With each animal acting as its own serum and liver control, ROC curves for the biomarkers were computed 
(Figure 8). In preliminary studies using a large and representative subset of serum samples, AFP-L3 levels <<  
the standard curve and this biomarker was discarded. Of the biomarkers queried, osteopontin (OPN), alpha-
fetoprotein (AFP) and Dickkopf-1 (DKK1) had AUROCs > 0.8 for HCC and Sn, Sp and thresholds for these 
biomarkers were computed (Table 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. ROC Curves for HCC Biomarkers: ROC curves are shown for AFP, DCP/PIVKA II, glypican-3, OPN, DKK1 and 
GP73. 
Table 3. Diagnostic Profile for OPN, AFP and DKK1. 
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Biomarker AUROC Sn (%) Sp (%) Threshold (ng/mL)
OPN 0.97 82 86 218
AFP 0.99 91 97 136
DKK1 0.89 82 81 2.4
Measurement of serum levels of OPN, AFP and DKK1 provides a framework for diagnosing HCC in this diet-
induced model of NASH (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Diagnostic Framework in NASH. Serum levels of OPN or AFP or DKK1 can be used to diagnose HCC in a diet-
induced model of NASH. 
Discussion 
 
In a murine model of FFD-induced NAFLD, animals developed NASH with increasing levels of fibrosis but not 
cirrhosis. Furthermore, approximately half the animals on FFD for 14 mo developed HCC. Analysis of a panel of 
serum-based biomarkers indicates that OPN, AFP and DKK1 are good diagnostics for HCC in NASH with 
AUCOCs of 0.97, 0.99 and 0.89, respectively and thresholds of 136 ng/mL, 218 ng/mL and 2.4 ng/mL, 
respectively. 
 
HCC is the fifth most common tumor worldwide and the second most common cause of cancer-related death7,8. 
Its incidence is increasing rapidly, primarily due to the HCV epidemic in the United States, and the hepatitis B 
virus epidemic in the Far East7,8,26. Fatty liver disease can also lead to HCC. With ~ 30% or adults in the United 
States having some steatosis, and 3-12% of adults in the United States having NASH, it is estimated that fatty 
liver disease-related HCC will overtake all other causes of primary liver cancer with the next 2 or 3 decades16.  
 
Within the continuum of liver disease, cirrhosis carries increased risk for HCC. In fact, the American Association 
of Liver Disease recommends surveillance of adults with cirrhosis every 6 months because early detection 
improves overall survival7,8. Very worrisome has been the recent increase of HCC in patients with NASH but no 
cirrhosis9.  In a review10 of the tumor board database at Brooke Army Medical Center (BAMC) 13% of the HCC 
cases occurred in non-cirrhotic NAFLD/NASH. In a study32 by Dyson and colleagues characterizing the 
demographics of HCC from 2000 to 2010 in the region surrounding Newcastle-upon-Tyne in North East England, 
~30% of the HCCs diagnosed occurred in the absence of cirrhosis, findings echoed by Paradis et al11 who 
reported development of HCC in patients with metabolic syndrome and the absence of significant liver fibrosis. 
In a clinical study12 by Ertle and colleagues, ~ 42% of individuals with NAFLD-NASH-HCC had no evidence of 
cirrhosis. Following a comprehensive survey of the clinical literature, Kolly and Dufour reported13 a 50% 
prevalence of HCC in the context of NASH without cirrhosis. These percentages translate to staggering numbers 
given that ~16 million people in the United States alone have NASH and ~5 million of those have NASH with 
advanced fibrosis16. Prognosis with HCC is often dismal with BCLC Stages 0 and A associated with better 
outcomes and BCLC Stages B-D deemed non-curative7,8,15. Patients with NASH-related HCC often present with 
large tumors and have a worse prognosis than those with other etiologies13. A retrospective analysis of the 
Surveillance, Epidemiology and End Results (SEER)-Medicare database, 50% of viral-hepatitis-infected patients 
with HCC died after one year, whereas 61% of the NAFLD patients with HCC died after one year33. Needless to 
say, there is an emergent need for HCC surveillance in the NASH patient. 
 
In the present study, we tracked animals randomized to a control or FFD for up to 14 mo in an attempt to simulate, 
at least, in part, fatty liver disease. The FFD included fat, cholesterol and fructose, a recipe that is associated 
with steatohepatitis17,18. Indeed, within 3 mo on this diet, animals had developed hallmark characteristics of 
NASH including elevated liver function tests. Some liver fibrosis, evidenced by a 50% increase in liver 
hydroxyproline content, was evident at 3 mo on this diet whereas by 14 mo on this diet animals presented with 
more advanced liver fibrosis. Picrosirius red is a marker of fibrillar collagen and use of this stain demonstrated a 
filigree network of collagen deposition, consistent with the development of liver fibrosis in this model. A salient 
and clinically relevant feature of this model is progression to HCC. While HCC has been reported34,35 in other 
models of diet-induced liver disease, those models typically combine a chemical such as streptocozocin or 
diethyl nitrosamine as a means to accelerate and aggravate liver pathology, often resulting in ~100% incidence 
of HCC in 12- 20 weeks. The FFD model described herein is designed to mimic a Western diet and has a more 
natural progression to HCC, similar to that observed clinically. The other salient and clinically relevant aspect of 
this model is the appearance of HCC in the absence of cirrhosis. In fact, at 14 mo on FFD, while animals 
developed liver fibrosis none of the animals had progressed to a cirrhotic phenotype. Absence of cirrhosis was 
evidenced by the filligree pattern of Picrosirius red staining, and is a finding consistent with other reports17,18 
using fatty diet models. In the present study, of the animals on FFD for 14 mo, 46% developed HCC, a percentage 
in excellent agreement with some of the clinical reports referenced above. ROC curve analysis showed that HCC 
is present in animals with increased liver mass, increased liver to body mass ratio and increased liver fibrosis, 
in as much as liver hydroxproline content is a marker of the same. These data suggest that in this murine FFD 
model, NASH with fibrosis results in HCC and supports the notion that this model is suitable for mimicking the 
clinical findings of NASH-related HCC in the absence of cirrhosis. 
 
Utilization of serum biomarkers has played a major role not only surveillance strategies in high-risk populations 
and achieving a diagnosis of HCC, but also in risk stratification and prediction of recurrence following initial 
therapy23-28.  AASLD guidelines recommend screening for HCC using ultrasound with or without serum AFP. 
Several serum markers for HCC have been identified in addition to AFP for diagnosis of HCC. These biomarkers 
include a fucosylated isoform of AFP reactive to Lens culinaris agglutinin, known as AFP-L3, glypican-3, OPN, 
GP73, the abnormal prothrombin vitamin K absence-II (PIVKA-II) also known as Des-gamma 
carboxyprothrombin (DCP) and DKK1, among others23-28. Many of these biomarkers are in clinical testing but 
other than AFP none has clinical approval. Furthermore, each of these biomarkers, including AFP, suffers from 
suboptimal Sn and Sp making its use as a standalone diagnostic unreliable. HCCs are not homogenous; each is 
different. Thus, some HCCs may have normal or only mildly elevated levels of AFP, but high levels of AFP-L3. 
Similarly, some of the tumors may have high levels of PIVKAII/DCP while having normal levels of AFP. Levels 
of many of these biomarkers including AFP are elevated in the setting of fatty liver and liver regeneration which 
can lead to a false positive diagnosis for HCC. With current data suggesting that no single biomarker alone is 
likely to have optimal Sn and Sp for the detection of HCC, particularly during early disease, combining biomarkers 
might represent a mechanism to improve diagnosis. In fact, gastroenterologists in Japan and the United Kingdom 
rely on BALAD-2 and GALAD calculators27 for diagnosing HCC albeit the scores are a function of disease 
etiology and are influence by regional differences.   
 
Following a comprehensive survey of the literature23-28, we queried a panel of serum-based HCC biomarkers 
(Table 1) to develop a diagnostic framework for HCC in our clinically relevant model NASH. A sample set of 76 
animals on 2 different diets and 2 different timepoints was used in this study with each animal acting as its own 
control. HCC was diagnosed by the presence of tumors on the liver coupled with histopathological confirmation 
of disease. Based on ROC analysis, 3 biomarkers, OPN, AFP and DKK1, and their thresholds, were identified 
with excellent diagnostic potential for HCC in NASH. Our empirical findings led us to a quantitative framework 
for diagnosis of NASH-related HCC without cirrhosis, which, to the best of our knowledge, is the first such 
description. The other biomarkers, viz. AFP-L3, PIVKAII/DCP, glypican-3 and GP73 performed poorly as 
diagnostics in this diet-induced model of NASH-related HCC; including the GALAD subset, AFP-L3 and 
PIVKAII/DCP. The reason(s) for their poor performance is beyond the scope of this study albeit it has been 
argued36 that a biomarker that consistently misdiagnoses disease can still find use by reversing (1-AUROC) the 
diagnosis.  
 
These findings are clinically relevant. Most importantly, risk for misdiagnosis of HCC is distributed amongst 3 
potentially independent diagnostics. Use of serum samples enables repeated sampling with minimal discomfort 
to the subject while minimizing the need for imaging studies. In addition to their use as a diagnostic, these 
biomarkers can be used to determine the efficacy of treatment strategies. Nevertheless, there are some 
limitations to these findings. It remains to be determined whether these findings are applicable to other models 
of NASH and to species other than the mouse. Second, tumor burden has not been correlated with biomarker 
levels. It would be important to conduct a longitudinal study coupling serum biomarker analysis with high 
resolution liver imaging, to determine how early HCC can be diagnosed in the setting of NASH and without the 
need to sacrifice the animals. Finally, the biomarkers queried is merely a subset of the HCC-related biomarkers 
described in the literature23-28 opening the possibility of expanding our findings. Nevertheless, this study 
represents, in our opinion, the initial step in the clinical diagnosis of NASH-HCC in the absence of cirrhosis.  
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